H-CPTENEPDL-OH

Ref. 3D-PP43087

Información del producto

• Nombre: H-CPTENEPDL-OH
• Sinónimos: NH2-Cys-Pro-Thr-Glu-Asn-Glu-Pro-Asp-Leu-OH

Descripción

Peptide H-CPTENEPDL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-CPTENEPDL-OH include the following: Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity V Rigo, MV Corrias, AM Orengo, A Brizzolara - Cancer Immunology , 2014 - Springerhttps://link.springer.com/article/10.1007/s00262-014-1536-9 Persistence of survivin specific T cells for seven years in a melanoma patient During domplete remission S Reker Hadrup, J Gehl , RB Sorensen - Cancer biology & , 2006 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.4161/cbt.5.5.2652 Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors S Nagaraj, V Pisarev , L Kinarsky - Journal of , 2007 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2007/02000/Dendritic_Cell_based_Full_length_Survivin_Vaccine.4.aspx Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer S Nagaraj, JI Youn, H Weber, C Iclozan, L Lu - Clinical cancer , 2010 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/16/6/1812/76077 Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen M Croce , R Meazza, AM Orengo, M Fabbi - Cancer Immunology , 2008 - Springerhttps://link.springer.com/article/10.1007/s00262-008-0496-3

• Marca: Biosynth